Suchergebnisse - "Tauzin, Alexandra"

PubPharm (13)

1

Intra-Host Evolution Analyses in an Immunosuppressed Patient Supports SARS-CoV-2 Viral Reservoir Hypothesis

enthalten in: Viruses | 2024

von Fournelle, D. | Mostefai, F. | Brunet-Ratnasingham, E. | +17

2

Humoral Responses Elicited by SARS-CoV-2 mRNA Vaccine in People Living with HIV

enthalten in: Viruses | 2023

von Marchitto, L. | Chatterjee, D. | Ding, S. | +10

3

A Recent SARS-CoV-2 Infection Enhances Antibody-Dependent Cellular Cytotoxicity against Several Omicron Subvariants following a Fourth mRNA Vaccine Dose

enthalten in: Viruses | 2023

von Beaudoin-Bussières, G. | Tauzin, A. | Dionne, K. | +9

4

Spike recognition and neutralization of SARS-CoV-2 Omicron subvariants elicited after the third dose of mRNA vaccine

enthalten in: Cell reports | 2023

von Tauzin, A. | Nicolas, A. | Ding, S. | +20

5

A boost with SARS-CoV-2 BNT162b2 mRNA vaccine elicits strong humoral responses independently of the interval between the first two doses

enthalten in: Cell reports | 2022

von Tauzin, A. | Gong, S. | Chatterjee, D. | +29

6

Temporal associations of B and T cell immunity with robust vaccine responsiveness in a 16-week interval BNT162b2 regimen

enthalten in: Cell reports | 2022

von Nayrac, M. | Dubé, M. | Sannier, G. | +30

UpdateOf: bioRxiv. 2021 Dec 21;:. - PMID 34981046

7

Evolution of Anti-RBD IgG Avidity following SARS-CoV-2 Infection

enthalten in: Viruses | 2022

von Tauzin, A. | Gendron-Lepage, G. | Nayrac, M. | +8

8

SARS-CoV-2 Omicron Spike recognition by plasma from individuals receiving BNT162b2 mRNA vaccination with a 16-week interval between doses

enthalten in: Cell reports | 2022

von Chatterjee, D. | Tauzin, A. | Marchitto, L. | +29

9

A Fc-enhanced NTD-binding non-neutralizing antibody delays virus spread and synergizes with a nAb to protect mice from lethal SARS-CoV-2 infection

enthalten in: Cell reports | 2022

von Beaudoin-Bussières, G. | Chen, Y. | Ullah, I. | +23

10

Strong humoral immune responses against SARS-CoV-2 Spike after BNT162b2 mRNA vaccination with a 16-week interval between doses

enthalten in: Cell host & microbe | 2022

von Tauzin, A. | Gong, S. | Beaudoin-Bussières, G. | +34